Manufacturing Today Issue - 241 October 2025 | Page 89

__________________________________________________________________________________________________________________ CPI
Beyond Pragmatic, CPI has engaged in many crucial projects. Frank highlights a case study that is particularly important to him.“ In the health and life sciences part of our business, we have been working with RNA, a focus that began before covid and was accelerated through the pandemic. As part of that, we established an RNA Centre of Excellence adjacent to our biologics manufacturing facility in Darlington. Recently, we announced a really important program in collaboration with the UK government and other partners, such as Wellcome Leap, as part of their global Biofoundry program. Our Darlington site has been selected as the location for the UK Biofoundry, which greatly enhances the capabilities that we have in that facility. This innovative manufacturing technology program aims to bring continuous manufacturing skills and approaches into the production of RNA therapies.
“ The health services and life sciences sectors are eager to explore RNA therapies for a broader range of diseases and conditions, including cancer, dementia, and other chronic diseases that are hard to treat. RNA therapies represent a promising area of medicine, and our ability to produce material for clinical trials in such an agile manner is crucial. As we often work with small patient groups, we only need to produce relatively modest amounts of material for trials. The agility provided by the Biofoundry model and its technology will give the UK a globally significant position in supporting innovative and cutting-edge RNA therapies.”
In June 2025, CPI opened a new Advanced Materials Battery Industrialisation Centre( AMBIC) in County Durham, a facility designed to accelerate the development of breakthrough battery materials.“ AMBIC represents a very strong collaboration stemming from the previous industrial
manufacturing-today. com 89